Fezolinetant - Latest Advances

Elinzanetant (Lynkuet) for menopausal vasomotor symptoms.

Journal: The Medical letter on drugs and therapeutics

Published: December 15, 2025

Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.

Journal: Expert review of clinical pharmacology

Published: October 15, 2025

Genetics of Idiopathic Hypogonadotropic Hypogonadism.

Journal: Journal of clinical research in pediatric endocrinology

Published: September 17, 2025

Fezolinetant Can Reduce Menopause Symptoms in Women Who Cannot or Will Not Take Hormone Therapy.

Journal: American family physician

Published: September 17, 2025

Treatment of Menopausal Symptoms When Hormone Therapy Is Contraindicated.

Journal: Seminars in reproductive medicine

Published: September 02, 2025

Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management.

Journal: Frontiers in reproductive health

Published: August 30, 2025

Neurokinin Antagonists to Treat Vasomotor Symptoms-Possible Implications for Long-Term Health and Disease.

Journal: Journal of clinical medicine

Published: August 29, 2025

Nonhormonal treatments for vasomotor symptoms.

Journal: Current opinion in obstetrics & gynecology

Published: July 31, 2025

Hopes and cautions with neurokinin antagonists for the management of vasomotor symptoms.

Journal: Maturitas

Published: July 13, 2025

Targeting vasomotor symptoms with the new drug fezolinetant - an expert overview.

Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Published: July 08, 2025

Fezolinetant for vasomotor symptoms in postmenopausal women.

Journal: Proceedings (Baylor University. Medical Center)

Published: June 25, 2025

Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a comprehensive systematic review and meta-analysis of randomized controlled trials.

Journal: Proceedings (Baylor University. Medical Center)

Published: June 25, 2025

Filters

Elinzanetant (Lynkuet) for menopausal vasomotor symptoms.

Elinzanetant (Lynkuet) for menopausal vasomotor symptoms.

Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.

Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.

Genetics of Idiopathic Hypogonadotropic Hypogonadism.

Genetics of Idiopathic Hypogonadotropic Hypogonadism.

Fezolinetant Can Reduce Menopause Symptoms in Women Who Cannot or Will Not Take Hormone Therapy.

Fezolinetant Can Reduce Menopause Symptoms in Women Who Cannot or Will Not Take Hormone Therapy.

Treatment of Menopausal Symptoms When Hormone Therapy Is Contraindicated.

Treatment of Menopausal Symptoms When Hormone Therapy Is Contraindicated.

Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management.

Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management.

Neurokinin Antagonists to Treat Vasomotor Symptoms-Possible Implications for Long-Term Health and Disease.

Neurokinin Antagonists to Treat Vasomotor Symptoms-Possible Implications for Long-Term Health and Disease.

Nonhormonal treatments for vasomotor symptoms.

Nonhormonal treatments for vasomotor symptoms.

Hopes and cautions with neurokinin antagonists for the management of vasomotor symptoms.

Hopes and cautions with neurokinin antagonists for the management of vasomotor symptoms.

Targeting vasomotor symptoms with the new drug fezolinetant - an expert overview.

Targeting vasomotor symptoms with the new drug fezolinetant - an expert overview.

Fezolinetant for vasomotor symptoms in postmenopausal women.

Fezolinetant for vasomotor symptoms in postmenopausal women.

Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a comprehensive systematic review and meta-analysis of randomized controlled trials.

Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a comprehensive systematic review and meta-analysis of randomized controlled trials.